Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q1

4544.TEDINET S100RLNC
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥56.6bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥260.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥65.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income−¥1.7bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥8.6bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income−¥1.5bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥22.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥8.5bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥1.2bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥8.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥289.6bnat 2023-06-30Cons.Assets
Total assets¥297.9bnat 2023-03-31Cons.Assets
Total assets¥278.3bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥139.8bnat 2023-06-30Cons.Liabilities
Total liabilities¥147.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥149.8bnat 2023-06-30Cons.Net assets
Net assets / equity¥150.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥146.0bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥32.7bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥44.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥32.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥39.7bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥6.2bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥4.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.7bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-19.672023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥98.252022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥98.242022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio51.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio52.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥1.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥1.6bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥36.1bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥36.1bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥18m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥2.8bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥14.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥13.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.3bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-06-30¥7.2bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.2bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-06-30¥355m
—segment totalrevenue2023-04-01 → 2023-06-30¥58.0bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥56.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥1.4bn
—segment totalsegment profit2023-04-01 → 2023-06-30−¥121m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥607m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥27m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥18.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥15.0bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-06-30¥440m
—segment totalrevenue2022-04-01 → 2022-06-30¥68.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥65.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 459
ItemContextValueUnit
Equity in losses of affiliates noePrior1YTDDuration768000000JPY
Equity in losses of affiliates noeCurrentYTDDuration253000000JPY
Loss on investments in capital noePrior1YTDDuration－JPY
Loss on investments in capital noeCurrentYTDDuration277000000JPY
Other noePrior1YTDDuration70000000JPY
Other noeCurrentYTDDuration145000000JPY
Non operating expensesPrior1YTDDuration933000000JPY
Non operating expensesCurrentYTDDuration772000000JPY
Ordinary incomePrior1YTDDuration8455000000JPY
Ordinary incomeCurrentYTDDuration-1468000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration0JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration－JPY
Gain on transfer of business eiPrior1YTDDuration－JPY
Gain on transfer of business eiCurrentYTDDuration377000000JPY
Extraordinary incomePrior1YTDDuration0JPY
Extraordinary incomeCurrentYTDDuration377000000JPY
Loss on valuation of investment securities elPrior1YTDDuration17000000JPY
Loss on valuation of investment securities elCurrentYTDDuration58000000JPY
Loss on valuation of investments in capital elPrior1YTDDuration149000000JPY
Loss on valuation of investments in capital elCurrentYTDDuration－JPY
Loss on valuation of other investments elPrior1YTDDuration67000000JPY
Loss on valuation of other investments elCurrentYTDDuration－JPY
Other elPrior1YTDDuration91000000JPY
Other elCurrentYTDDuration16000000JPY
Extraordinary lossPrior1YTDDuration326000000JPY
Extraordinary lossCurrentYTDDuration75000000JPY
Income before income taxesPrior1YTDDuration8128000000JPY
Income before income taxesCurrentYTDDuration-1165000000JPY
Income taxes currentPrior1YTDDuration840000000JPY
Income taxes currentCurrentYTDDuration453000000JPY
Income taxes deferredPrior1YTDDuration1700000000JPY
Income taxes deferredCurrentYTDDuration-499000000JPY
Income taxesPrior1YTDDuration2541000000JPY
Income taxesCurrentYTDDuration-45000000JPY
Profit lossPrior1YTDDuration5587000000JPY
Profit lossCurrentYTDDuration-1120000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration5587000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-1120000000JPY
Profit lossPrior1YTDDuration5587000000JPY
Profit lossCurrentYTDDuration-1120000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-293000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration259000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration4074000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration3757000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration51000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration44000000JPY
Other comprehensive incomePrior1YTDDuration3832000000JPY
Other comprehensive incomeCurrentYTDDuration4061000000JPY
Comprehensive incomePrior1YTDDuration9420000000JPY
Comprehensive incomeCurrentYTDDuration2940000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass